List of Excipients in Branded Drug TUSSICAPS

Generic Drugs Containing TUSSICAPS

Company	Ingredient	NDC	Excipient
Bausch Health US LLC	hydrocodone polistirex and chlorpheniramine polistirex	0187-0108	ALCOHOL
Bausch Health US LLC	hydrocodone polistirex and chlorpheniramine polistirex	0187-0108	AMMONIA
Bausch Health US LLC	hydrocodone polistirex and chlorpheniramine polistirex	0187-0108	BUTYL ALCOHOL
Bausch Health US LLC	hydrocodone polistirex and chlorpheniramine polistirex	0187-0108	CELLULOSE, MICROCRYSTALLINE
Bausch Health US LLC	hydrocodone polistirex and chlorpheniramine polistirex	0187-0108	D&C BLACK NO. 2
Bausch Health US LLC	hydrocodone polistirex and chlorpheniramine polistirex	0187-0108	D&C YELLOW NO. 10
Bausch Health US LLC	hydrocodone polistirex and chlorpheniramine polistirex	0187-0108	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in TUSSICAPS?

# Of NDCs	Excipient
2	ALCOHOL
1	ALUMINUM OXIDE
2	AMMONIA
2	BUTYL ALCOHOL
2	CELLULOSE, MICROCRYSTALLINE
1	D&C BLACK NO. 2
2	D&C YELLOW NO. 10

TUSSICAPS Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

TUSSICAPS is an extended-release oral capsule combining hydrocodone bitartrate and chlorpheniramine maleate for cough and upper-respiratory symptoms. Its commercial value is tied less to active-ingredient exclusivity than to controlled-release performance, abuse-deterrent design, manufacturing reliability, and compliance with FDA requirements for opioid products. The strongest development opportunity is a technically differentiated generic or reformulated extended-release capsule that matches pharmacokinetic performance while improving tamper resistance, dose uniformity, and supply economics.

What is TUSSICAPS and which excipient functions define the product?

TUSSICAPS contains hydrocodone bitartrate and chlorpheniramine maleate in an extended-release capsule dosage form. Hydrocodone is an opioid controlled under the U.S. Controlled Substances Act; chlorpheniramine is a first-generation antihistamine. The FDA-approved product is prescription-only and carries opioid-related warnings, including risks of respiratory depression, misuse, addiction, abuse, and accidental ingestion (FDA, TUSSICAPS Prescribing Information).

The excipient system must perform four separate functions:

1. Control release of both active ingredients.
2. Maintain capsule fill uniformity at low drug loading.
3. Prevent dose dumping in the presence of alcohol or mechanical manipulation.
4. Support stable manufacturing and acceptable capsule appearance.

The two active ingredients create a difficult formulation problem. Hydrocodone and chlorpheniramine have different physicochemical properties, dose levels, and release requirements. A single matrix may not control both compounds consistently. Multiparticulate pellets, coated particles, or separate release-control populations are more commercially defensible than a basic hydrophilic matrix capsule.

What excipients are most commercially relevant for TUSSICAPS?

The highest-value excipient categories are release-control polymers, pellet substrates, coating systems, flow aids, lubricants, capsule-shell materials, and taste or abuse-deterrence modifiers.

Release-control polymers

Potential polymer platforms include:

• Ethylcellulose for water-insoluble membrane coatings.
• Hypromellose for hydrophilic matrix systems.
• Polyvinyl acetate-based systems for sustained-release matrices.
• Methacrylate copolymers for pH-responsive or permeability-controlled coatings.
• Cellulose acetate and related semipermeable membrane materials for osmotic or diffusion-controlled systems.
• Carbomers or other swellable polymers for gel-forming matrices.

For TUSSICAPS, ethylcellulose or a comparable water-insoluble coating is commercially attractive because it can support multiparticulate extended release and provide adjustable permeability. Hypromellose is simpler and generally less expensive, but a conventional hydrophilic matrix may be more vulnerable to alcohol-induced release changes and mechanical disruption.

Pellet substrates and binders

Sugar spheres, microcrystalline cellulose spheres, or inert polymeric starter cores can support drug layering. Common binder choices include povidone, hypromellose, hydroxypropyl cellulose, and starch-based materials.

Microcrystalline cellulose is attractive for low-cost scale-up and robust fluid-bed processing. Sugar spheres can produce reliable coating surfaces but may create greater control challenges related to moisture, density, and capsule fill weight.

Plasticizers and coating aids

Coating systems may use triethyl citrate, diethyl phthalate, polyethylene glycol, or other approved plasticizers. Selection affects:

• Film flexibility.
• Permeability.
• Residual solvent profile.
• Coating uniformity.
• Long-term storage stability.
• Processability in fluid-bed equipment.

Triethyl citrate is often favored where a lower regulatory and toxicological burden is commercially important. Plasticizer migration and coating aging require evaluation during accelerated and long-term stability studies.

Lubricants and flow-control excipients

Magnesium stearate, colloidal silicon dioxide, talc, and sodium stearyl fumarate can improve manufacturing performance. The formulation team must control lubricant concentration and blending time because excessive lubrication can reduce pellet wettability and alter dissolution.

Colloidal silicon dioxide can improve flow in low-dose capsule blends. Talc can improve coating processability but requires tight control of particle characteristics and impurity specifications.

Capsule shells

Hard gelatin capsules are the conventional platform. Hydroxypropyl methylcellulose capsules can offer advantages in moisture control, vegetarian positioning, and compatibility with certain fill materials.

For an opioid product, capsule-shell selection also affects tamper testing. A shell that rapidly dissolves after opening may facilitate powder access. A shell with higher mechanical strength or an integrated tamper-evident design can support abuse-deterrence claims, although the shell alone is unlikely to satisfy FDA abuse-deterrent expectations.

How should a TUSSICAPS excipient platform be designed?

A competitive formulation should use separate control of hydrocodone and chlorpheniramine unless development data demonstrate that one release system controls both drugs adequately.

Preferred platform: multiparticulate extended-release capsule

A practical design is:

• Hydrocodone-loaded coated pellets.
• Chlorpheniramine-loaded coated pellets.
• Separate immediate-release or delayed-release fractions only if clinically justified.
• Final capsule filling with flow-control excipients.
• A coating system resistant to alcohol-triggered dose dumping.

This platform offers independent adjustment of each active ingredient’s release profile. It also permits different drug-layering conditions, coating weights, and particle-size distributions.

Lower-cost platform: hydrophilic matrix capsule

A matrix capsule using hypromellose or polyvinyl acetate may reduce manufacturing cost and simplify equipment requirements. Its disadvantages include:

• Greater sensitivity to compression and mechanical damage.
• Potential food and alcohol effects.
• Less flexibility in independently controlling two active ingredients.
• More difficult optimization of in vitro-in vivo correlation.

This approach is more appropriate for a conventional generic strategy where the reference product has a matrix architecture and the regulatory pathway accepts comparative dissolution and pharmacokinetic data.

Higher-barrier platform: abuse-deterrent multiparticulate system

A differentiated product could combine:

• High-viscosity polymers that form a difficult-to-syringe gel.
• Coatings that resist rapid solvent penetration.
• Particle systems that remain physically difficult to crush.
• Denaturing or aversive excipients, where legally and clinically appropriate.
• Capsule designs that reduce ease of tampering.

FDA evaluates abuse-deterrent products through laboratory, pharmacokinetic, and human abuse-potential evidence. A formulation cannot make broad abuse-deterrent claims solely because it uses a controlled-release polymer (FDA, 2015).

What FDA regulatory pathway applies to a TUSSICAPS generic?

A generic version would generally proceed under an abbreviated new drug application, provided the reference product remains suitable for ANDA comparison and the applicant can demonstrate pharmaceutical equivalence and bioequivalence.

Key regulatory issues include:

Issue	TUSSICAPS relevance
Active ingredients	Hydrocodone bitartrate and chlorpheniramine maleate
Dosage form	Extended-release capsule
Controlled substance	Hydrocodone creates DEA and controlled-substance manufacturing obligations
Bioequivalence	May require fasting, fed, alcohol-interaction, and multiple-dose studies
Dissolution	Extended-release profiles for both active ingredients are critical
Abuse deterrence	Required only if the applicant pursues abuse-deterrent labeling or must match a reference product with that attribute
Manufacturing	Schedule II controls, security, inventory reconciliation, and quota compliance
Labeling	Must match the reference labeling unless FDA permits a lawful difference
Orange Book	FDA Orange Book status determines listed patents, exclusivity, and reference-product availability

Extended-release products often require more extensive bioequivalence assessment than immediate-release generics. The applicant must also evaluate food effects and alcohol-induced dose dumping because these factors can materially alter opioid exposure.

What patents protect TUSSICAPS and when does exclusivity expire?

The commercial opportunity depends on the current FDA Orange Book record for the applicable TUSSICAPS reference product and any listed patents covering the formulation, method of use, or delivery technology. Active-ingredient patents for hydrocodone and chlorpheniramine are not the principal barrier. The relevant rights are more likely to concern:

• Extended-release capsule architecture.
• Coated multiparticulate systems.
• Hydrocodone and antihistamine release profiles.
• Alcohol-resistant delivery.
• Abuse-deterrent formulations.
• Manufacturing processes for drug-layered pellets.
• Methods of treating cough with the combination product.

An applicant should distinguish three separate dates:

1. Patent expiration date.
2. FDA statutory exclusivity expiration.
3. Commercial availability of an ANDA after approval and any Paragraph IV litigation.

The Orange Book must be checked by product, strength, dosage form, and reference-listed applicant. Patent listings can change through delisting, expiration, court decisions, or FDA administrative action. No reliable commercial conclusion should be based solely on historical TUSSICAPS launch materials or a legacy patent family.

What Paragraph IV risks exist for TUSSICAPS?

A generic applicant may certify under Paragraph IV that listed patents are invalid, unenforceable, or not infringed. A notice letter can trigger patent litigation under the Hatch-Waxman framework. The principal litigation risk would arise from formulation or controlled-release patents rather than composition-of-matter claims.

Potential applicant positions include:

• The proposed capsule does not practice the claimed pellet structure.
• The release-control polymer or coating differs from the claimed system.
• The claims are anticipated or obvious in view of prior controlled-release opioid formulations.
• The patent is unenforceable because of prosecution or disclosure defects.
• The product does not infringe method-of-use claims because of labeling differences.

A non-infringing formulation strategy should avoid unnecessary overlap with claimed coating compositions, polymer ratios, pellet populations, and manufacturing sequences.

How strong is the TUSSICAPS patent estate?

The patent estate should be assessed as a formulation estate rather than an active-ingredient estate. Its strength depends on claim breadth, remaining patent term, prosecution history, written-description support, and whether the claims require specific excipient combinations.

Stronger claim types

Claims are generally more defensible when they cover:

• A defined release profile linked to measurable dissolution parameters.
• A specific multiparticulate architecture.
• A controlled-release coating with defined permeability or weight gain.
• A formulation that limits alcohol-induced dose dumping.
• A manufacturing process that produces a critical particle-size or coating attribute.

Weaker claim types

Risk is generally higher for claims that cover:

• Broad lists of conventional polymers.
• Generic extended-release capsules without structural limitations.
• Routine combinations of hydrocodone, antihistamines, and common excipients.
• Functional language unsupported by comparative data.
• Formulations that rely on predictable polymer substitution.

A freedom-to-operate review should cover U.S., European, Canadian, Australian, and selected Asian patent families because excipient and delivery patents frequently have different claim scope across jurisdictions.

What commercial opportunities exist for TUSSICAPS?

Generic extended-release capsule

The clearest opportunity is a lower-cost generic capsule, subject to the status of the reference product and FDA’s ability to accept it for ANDA development. The product has a technically difficult formulation profile, which can reduce the number of capable competitors.

Commercial advantages include:

• Limited competition compared with immediate-release opioid products.
• Potential premium for reliable extended-release performance.
• Specialist value for manufacturers with controlled-substance infrastructure.
• Opportunity to use existing pellet-coating capacity.

Commercial disadvantages include:

• Small or declining market for prescription opioid cough products.
• Tight FDA and DEA oversight.
• High liability exposure.
• Prescriber and payer movement away from opioid cough medicines.
• Potential reference-product discontinuation or supply instability.

Authorized generic or contract manufacturing

A controlled-substance manufacturer could pursue:

• An authorized generic arrangement.
• Contract manufacture for an established pharmaceutical company.
• Technology licensing for multiparticulate release systems.
• Supply of coated pellets rather than finished capsules.

This route may create value without requiring the developer to build a full commercial sales organization.

Reformulated abuse-deterrent product

An abuse-deterrent version could target institutional and specialty channels, but the development burden would be materially higher. The product would need evidence supporting the proposed abuse-deterrent properties and a commercial rationale strong enough to justify clinical, regulatory, manufacturing, and post-market costs.

Non-opioid successor product

A longer-term opportunity is to use the TUSSICAPS excipient and capsule platform for a non-opioid cough product. Potential candidates include combinations involving dextromethorphan, benzonatate, antihistamines, or other antitussive agents. This would reduce controlled-substance restrictions but would require new clinical positioning, formulation work, and potentially a new regulatory pathway.

How does TUSSICAPS compare with competing cough products?

Product category	Main commercial strength	Main weakness	Excipient opportunity
TUSSICAPS-type hydrocodone/chlorpheniramine ER capsule	Extended symptom control and differentiated dosage form	Opioid restrictions and safety concerns	Alcohol-resistant multiparticulates
Hydrocodone/chlorpheniramine suspension	Familiar liquid presentation	Dosing variability, storage and handling issues	Suspension rheology and dose uniformity
Dextromethorphan products	Non-opioid positioning and broad consumer use	High competition and lower differentiation	Taste masking and sustained release
Benzonatate capsules	Non-opioid prescription option	Swallowing and accidental-ingestion concerns	Safer shell and tamper-resistant design
Antihistamine/decongestant combinations	Large addressable market	Heavy generic competition	Modified release and reduced sedation
OTC liquid cough products	Broad access and high distribution	Low margin and crowded shelf space	Alcohol-free, sugar-free, child-resistant packaging

TUSSICAPS has a narrower market than non-opioid alternatives. Its formulation complexity may support higher technical barriers, but the commercial ceiling is constrained by opioid prescribing and regulatory risk.

What manufacturing and IP barriers affect commercial entry?

The principal barriers are not the cost of capsule filling. They are controlled-release process control, opioid security, and reproducible bioavailability.

Critical manufacturing capabilities include:

• Fluid-bed drug layering.
• Uniform polymer coating at commercial scale.
• In-process particle-size and coating-weight control.
• Low-dose blend uniformity.
• Segregation control during capsule filling.
• Alcohol-dissolution testing.
• Controlled-substance inventory reconciliation.
• Secure storage and destruction procedures.
• Cleaning validation for potent opioid residues.

The most valuable know-how may be retained as trade secrets rather than claimed in patents. Examples include coating endpoint determination, solvent-system selection, curing conditions, pellet blending ratios, and capsule-fill segregation controls.

What is the revenue exposure and market-entry risk?

TUSSICAPS revenue potential should be treated as niche and structurally exposed to opioid-market contraction. A business case should model:

• Historical and current prescription volume.
• Reference-product availability.
• Average selling price by payer channel.
• Number of approved or pending ANDAs.
• FDA shortage status.
• DEA quota availability.
• Litigation timing.
• Expected payer substitution.
• Product-liability reserves.
• Manufacturing yield and controlled-substance security costs.

A generic launch could be attractive if the market has limited approved suppliers and the applicant can achieve a first-to-market position. The opportunity is weaker if the reference product is discontinued, demand is low, or FDA requires extensive clinical bridging because the reference product has an unusual release profile.

Key Takeaways

• TUSSICAPS is an extended-release hydrocodone bitartrate and chlorpheniramine maleate capsule.
• Multiparticulate coating is the strongest platform for independently controlling release of both active ingredients.
• Ethylcellulose, hypromellose, polyvinyl acetate, methacrylate copolymers, and cellulose-based systems are the principal excipient families for development.
• The commercial barrier is formulation performance, not active-ingredient patent protection.
• A generic strategy must address extended-release bioequivalence, food effects, alcohol-induced dose dumping, and controlled-substance compliance.
• The most realistic commercial paths are a generic capsule, authorized generic supply, contract manufacturing, or licensing of a release-control platform.
• An abuse-deterrent reformulation could create differentiation but would require substantial FDA evidence.
• The market is commercially constrained by opioid safety policy, prescribing trends, liability risk, and DEA controls.
• Current patent and exclusivity conclusions require product-specific review of the FDA Orange Book and relevant patent families.

FAQs

Can TUSSICAPS be reformulated as a tablet?

Yes. A tablet could use a hydrophilic matrix, multilayer design, osmotic system, or coated mini-tablets. A tablet would need to reproduce the reference product’s release and exposure profile, which may make it unsuitable for a straightforward ANDA if the reference dosage form remains a capsule.

Which excipient is best for preventing hydrocodone dose dumping?

No single excipient establishes dose-dumping resistance. A controlled-permeability coating, robust multiparticulate architecture, and alcohol-interaction testing are more important than selection of one polymer. Ethylcellulose and related insoluble coating systems are practical starting points.

Does TUSSICAPS qualify for biosimilar competition?

No. TUSSICAPS is a small-molecule drug product, not a biologic. Competition would occur through an ANDA or, for a materially different formulation or indication, a full or abbreviated drug application pathway.

Could a TUSSICAPS generic use different inactive ingredients?

Potentially. A generic may use different excipients if it meets FDA requirements for pharmaceutical equivalence, safety, performance, stability, bioequivalence, and labeling. Differences that affect release, absorption, tolerability, or capsule performance can create additional regulatory requirements.

Is a non-opioid TUSSICAPS successor commercially attractive?

A non-opioid successor could have broader regulatory and commercial appeal because it would avoid Schedule II controls. Its value would depend on clinical efficacy, differentiated duration of action, taste or swallowing performance, and the ability to obtain meaningful market protection.

References

1. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. https://www.fda.gov
2. U.S. Food and Drug Administration. (n.d.). TUSSICAPS prescribing information. FDA-approved product labeling.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2014). Extended release and long acting opioids: Risk evaluation and mitigation strategy. https://www.fda.gov
5. U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP Convention.
6. U.S. Code, 21 U.S.C. §§ 355 and 355(j). Federal Food, Drug, and Cosmetic Act provisions governing abbreviated new drug applications and patent certifications.